STOCK TITAN

[Form 3] ATOSSA THERAPEUTICS, INC. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Atossa Therapeutics (ATOS) filed a Form 3 initial statement of beneficial ownership for its Chief Financial Officer, Mark James Daniel, with a date of event of 10/14/2025. The filing states that no securities are beneficially owned. The submission includes an Exhibit 24 Power of Attorney and is filed by one reporting person.

Atossa Therapeutics (ATOS) ha presentato una dichiarazione iniziale del possesso beneficiario (Form 3) per il suo Chief Financial Officer, Mark James Daniel, con data dell’evento del 14/10/2025. La dichiarazione indica che nessun titolo è detenuto beneficiariamente. La sottomissione include un Power of Attorney dell’Allegato 24 ed è presentata da un solo reportante.

Atossa Therapeutics (ATOS) presentó una declaración inicial Form 3 de titularidad beneficiosa para su Director financiero, Mark James Daniel, con fecha de evento del 14/10/2025. La presentación indica que ningún valor es propiedad beneficiaria. La entrega incluye un Poder General (Power of Attorney) del Exhibit 24 y es presentada por una sola persona reportante.

Atossa Therapeutics (ATOS)Chief Financial OfficerMark James Daniel을 위한 초기 유익소유 공시(Form 3)를 14/10/2025의 이벤트 날짜와 함께 제출했습니다. 신청서는 경제적 이익으로 보유한 증권이 없다고 명시합니다. 제출에는 Exhibit 24의 Power of Attorney가 포함되며, 단일 보고자에 의해 제출됩니다.

Atossa Therapeutics (ATOS) a déposé une déclaration initiale de propriété bénéficiaire (Form 3) pour son Chief Financial Officer, Mark James Daniel, avec une date d'événement du 14/10/2025. Le dépôt indique que aucune valeur mobilière n'est détenue bénéficiairement. La soumission comprend une procuration (Power of Attorney) de l'Exhibit 24 et est déposée par une seule personne déclarant.

Atossa Therapeutics (ATOS) hat eine Form 3, ursprüngliche Stellungnahme zur wirtschaftlich Berechtigten (Beneficial Ownership), für ihren Chief Financial Officer, Mark James Daniel, eingereicht, mit dem Ereignisdatum 14.10.2025. Die Einreichung besagt, dass keine Wertpapiere wirtschaftlich berechtigt gehalten werden. Die Einreichung enthält eine Exhibit 24 Vollmacht (Power of Attorney) und wird von einer meldenden Person eingereicht.

Atossa Therapeutics (ATOS) قدمت بيان الملكية المستفيدة الأولي (Form 3) لـالمسؤول التنفيذي المالي وشاغل المنصب Mark James Daniel، بتاريخ الحدث 14/10/2025. يورد الملف أن لا تمتلك أي أوراق مالية بشكل مستفيد. يتضمن التقديم توكيلاً من Exhibit 24 وهو مقدّم من قبل شخص واحد مُبلِّغ.

Atossa Therapeutics (ATOS) 已为其 首席财务官, Mark James Daniel, 提交了 Form 3 初始受益所有权声明,事件日期为2025/10/14。该申报表示并无受益所有的证券。该提交包含 Exhibit 24 的授权书(Power of Attorney),并由一名申报人提交。

Positive
  • None.
Negative
  • None.

Atossa Therapeutics (ATOS) ha presentato una dichiarazione iniziale del possesso beneficiario (Form 3) per il suo Chief Financial Officer, Mark James Daniel, con data dell’evento del 14/10/2025. La dichiarazione indica che nessun titolo è detenuto beneficiariamente. La sottomissione include un Power of Attorney dell’Allegato 24 ed è presentata da un solo reportante.

Atossa Therapeutics (ATOS) presentó una declaración inicial Form 3 de titularidad beneficiosa para su Director financiero, Mark James Daniel, con fecha de evento del 14/10/2025. La presentación indica que ningún valor es propiedad beneficiaria. La entrega incluye un Poder General (Power of Attorney) del Exhibit 24 y es presentada por una sola persona reportante.

Atossa Therapeutics (ATOS)Chief Financial OfficerMark James Daniel을 위한 초기 유익소유 공시(Form 3)를 14/10/2025의 이벤트 날짜와 함께 제출했습니다. 신청서는 경제적 이익으로 보유한 증권이 없다고 명시합니다. 제출에는 Exhibit 24의 Power of Attorney가 포함되며, 단일 보고자에 의해 제출됩니다.

Atossa Therapeutics (ATOS) a déposé une déclaration initiale de propriété bénéficiaire (Form 3) pour son Chief Financial Officer, Mark James Daniel, avec une date d'événement du 14/10/2025. Le dépôt indique que aucune valeur mobilière n'est détenue bénéficiairement. La soumission comprend une procuration (Power of Attorney) de l'Exhibit 24 et est déposée par une seule personne déclarant.

Atossa Therapeutics (ATOS) hat eine Form 3, ursprüngliche Stellungnahme zur wirtschaftlich Berechtigten (Beneficial Ownership), für ihren Chief Financial Officer, Mark James Daniel, eingereicht, mit dem Ereignisdatum 14.10.2025. Die Einreichung besagt, dass keine Wertpapiere wirtschaftlich berechtigt gehalten werden. Die Einreichung enthält eine Exhibit 24 Vollmacht (Power of Attorney) und wird von einer meldenden Person eingereicht.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Daniel Mark James

(Last) (First) (Middle)
C/O ATOSSA THERAPEUTICS, INC.
10202 5TH AVENUE NE SUITE 200

(Street)
SEATTLE WA 98125

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/14/2025
3. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Mark James Daniel 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ATOS file?

A Form 3 initial statement of beneficial ownership.

Who is the reporting person on ATOS’s Form 3?

Mark James Daniel, the company’s Chief Financial Officer.

What is the date of the event on the Form 3 for ATOS?

The date of event is 10/14/2025.

Does the CFO report owning ATOS securities?

The filing states no securities are beneficially owned.

Is this Form 3 filed by multiple reporting persons?

No. It is filed by one reporting person.

Does the filing include a Power of Attorney?

Yes. Exhibit 24 - Power of Attorney is included.
Atossa Therapeutics Inc

NASDAQ:ATOS

ATOS Rankings

ATOS Latest News

ATOS Latest SEC Filings

ATOS Stock Data

124.64M
129.08M
0.07%
21.17%
2.77%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE